International journal of clinical oncology
-
Int. J. Clin. Oncol. · Apr 2020
Multicenter Study Observational StudyPrognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Although regorafenib or trifluridine/tipiracil (FTD/TPI) has been recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC), not all patients have beneficial outcomes. This study aimed to develop a prognostic scoring system for evaluating the overall survival (OS) benefit. ⋯ These prognostic scores are useful for identifying patients with mCRC who will obtain survival benefits from these drugs.